Publications
559
Citations
24,566
Est. group size
~14
Recurring co-author estimate
Active years
39
Publishing since 1988
Raymond L. Benza's research centers on pulmonary arterial hypertension (a disease causing high blood pressure in the lung arteries that strains the heart) and related heart and valve conditions, including how the right side of the heart adapts to increased pressure. His work spans clinical trials of drug therapies, risk-assessment tools, remote monitoring devices, and catheter-based treatments for heart valve disease.
Publication output rose to a peak around 2020, declined through 2022-2023, and has partially recovered since, though recent-year counts appear lower partly due to still-incomplete data for 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 26-A-19526-ACC EARLY AND HIGH-DOSE TREPROSTINIL THERAPY TARGETING PRESSURE TO IMPROVE RIGHT VENTRICULAR FUNCTION IN PULMONARY ARTERIAL HYPERTENSION: ARTISAN INTERIM ANALYSIS
Journal of the American College of Cardiology · 2026
- Combined Snare and Buddy-Balloon Strategy for Failed Valve Crossing in Valve-in-Valve Transcatheter Aortic Valve Replacement
JACC Case Reports · 2026
- Balloon Aortic Valvuloplasty as a Bridge Therapy in Acute Valve Syndrome: A Narrative Review of Evidence Gaps and Future Directions
Structural Heart · 2026
- Transatrial Balloon-Expandable Valve Implantation for Severe Mitral Annular Calcification With Native Leaflet Sealing
JACC Case Reports · 2026
- Platypnea-Orthodeoxia Syndrome Caused by a Patent Foramen Ovale and Interatrial Septal Aneurysm: A Case Report
Cureus · 2026
- Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial
Circulation · 2025
- TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension
Circulation Heart Failure · 2025
- Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Journal of the American Heart Association · 2025
- Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study
Advances in Therapy · 2025
- Association of the Right Ventricle Cardiac Power Index with Glucose Metabolism and Prognosis in Pulmonary Arterial Hypertension Patients—PET/MRI Study
Journal of Clinical Medicine · 2025
- TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment
Pneumologie · 2025
- Remote monitoring in pulmonary arterial hypertension
European Respiratory Society eBooks · 2025
- Abstract 4367586: Safety Profile of the CardioMEMS HF System in Pulmonary Arterial Hypertension: A Pooled Adverse Event Analysis from Three Clinical Studies
Circulation · 2025
- Abstract 4361924: Right heart dimensions and pulmonary arterial wedge pressure in pulmonary arterial hypertension: exploring a controversial relationship
Circulation · 2025
- Physiologic Markers of Mortality in Acute Valve Syndrome: An Ischemic Physiology Score Stratifies Patient Risk
Structural Heart · 2025
- The Journal of Heart and Lung Transplantation×61
- CHEST Journal×36
- Circulation×26
- Pulmonary Circulation×24
- Journal of the American College of Cardiology×18
- Verónica Franco
Medicine · The Ohio State University
- Rachel D’Amico
Medicine · The Ohio State University
- Shili Lin
Medicine · The Ohio State University
- Priscilla Correa‐Jaque
Medicine · The Ohio State University
- Rebecca Vanderpool
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile